

J. Timothy Meigs  
Sector Patent Counsel

Genetic Therapy, Inc.  
9 West Watkins Mill Road  
Gaithersburg, MD 20878

Tel (301) 258-4715  
Fax (301) 258-4620  
Email: tim.meigs@pharma.novartis.com



**GENETIC THERAPY, INC.**  
A Novartis Company

**Fax**

**FAX RECEIVED**

Attention Examiner Bronwen Loeb, PTO Art Unit 1636

AUG 09 2002

Fax no. (703) 308-4242

**GROUP 1600**

Number of  
pages 21

Date August 9, 2002


OFFICIAL

RE: 09/715,249

Dear Examiner Loeb,

Attached hereto for filing in 09/715,249 are a Reply Under 37 CFR §1.111 With Amendment including a petition for a three month extension of time and a Fee Transmittal Sheet.

Respectfully submitted,

  
J. Timothy Meigs  
Reg. No. 38,241  
Attorney for Applicant

---

*PRIVILEGED AND CONFIDENTIAL information intended only for the use of the addressee(s) named above. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. Anyone who receives this communication in error should notify us immediately by telephone and return the original to us at the address above via the U.S. Mail. Thank you.*

---

 NOVARTIS

**CERTIFICATE OF FACSIMILE TRANSMISSION**

I hereby certify that this paper is being facsimile transmitted to the  
Patent Office Fax No. (703) 308-4242 on the date shown below.

J. Timothy Meigs  
Type or Print Name

*J. Timothy Meigs*  
Signature

8/9/02  
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re Application of:**

Pippig et al.

Confirmation No. 7928

App. No. 09/715,249

Art Unit: 1636

Filed: November 17, 2000

**Examiner: Bronwen Loeb**

**For: Selectable Cell Surface Marker Genes**

Atty Docket: 4-31192A

**REPLY UNDER 37 CFR § 1.111 WITH AMENDMENT**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Office Action dated February 9, 2002, please enter the amendments set forth below consider the following remarks.

An Extension of Time for three months is hereby requested pursuant to 37 C.F.R. §1.136(a). Please charge Deposit Account No. 19-0134 (in the name of Novartis Pharmaceutical Corporation) in the amount of \$920.00 for payment of the extension fee. The Commissioner is authorized to charge any additional fees under 37 C.F.R. §1.17 that may be required, or credit any overpayment, to Novartis Pharmaceutical Corporation's Deposit Account No. 19-0134.

01 FC:117	920.00 CH
02 FC:103	190.00 CH
03 FC:102	84.00 CH